High Alert
Ars Technica

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck sayWorldPing

The vaccine reportedly thwarted the cancer's return and spread.

This is a short WorldPing brief. The full report was published by Ars Technica.

Read the full report at Ars Technica

Related news